MCID: DDN010
MIFTS: 42

Duodenum Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Duodenum Cancer

MalaCards integrated aliases for Duodenum Cancer:

Name: Duodenum Cancer 12 15
Duodenal Benign Neoplasm 12 15
Duodenal Neoplasms 44 73
Duodenal Cancer 12 73
Malignant Neoplasm of Duodenum 73
Neoplasm of the Duodenum 12
Neoplasm of Duodenum 12
Cancer of Duodenum 12
Duodenal Carcinoma 55
Duodenal Neoplasm 12
Cancer, Duodenal 40

Classifications:



External Ids:

Disease Ontology 12 DOID:10021 DOID:1737
ICD10 33 C17.0
ICD9CM 35 152.0
MeSH 44 D004379

Summaries for Duodenum Cancer

Disease Ontology : 12 A small intestine cancer that is located in the beginning section of the small intestine.

MalaCards based summary : Duodenum Cancer, also known as duodenal benign neoplasm, is related to duodenum adenocarcinoma and familial adenomatous polyposis, and has symptoms including abdominal pain An important gene associated with Duodenum Cancer is KRT7 (Keratin 7), and among its related pathways/superpathways are Gastric cancer and Diseases of glycosylation. The drugs Ursodeoxycholic acid and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include small intestine, lung and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Duodenal cancer is a cancer in the first section of the small intestine known as the duodenum. Cancer of... more...

Related Diseases for Duodenum Cancer

Diseases related to Duodenum Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 232)
# Related Disease Score Top Affiliating Genes
1 duodenum adenocarcinoma 31.3 CDX2 KRAS KRT7 MUC2 MUC6
2 familial adenomatous polyposis 30.3 KRAS MUTYH NTHL1
3 gastric cancer 29.7 CDX2 KRAS MUC2 MUC6 MUTYH
4 mutyh-associated polyposis 29.6 KRAS MUTYH
5 lynch syndrome 29.4 KRAS MUC2 MUTYH
6 villous adenoma 29.4 CDX2 KRAS MUC1 SST
7 adenoma 29.4 KRAS MEN1 MUTYH SST
8 pancreatic cancer 28.7 CDX2 HRAS KRAS MEN1 MUC1 MUC2
9 colorectal cancer 28.4 CDX2 HRAS KRAS KRT7 MUC1 MUC2
10 duodenum adenoma 11.2
11 alveoli adenoma 10.3 KRAS KRT7
12 prostate squamous cell carcinoma 10.3 HRAS KRT7
13 secondary hypertrophic osteoarthropathy 10.3 HRAS KRAS
14 ovarian cystadenocarcinoma 10.3 HRAS KRAS
15 acneiform dermatitis 10.3 HRAS KRAS
16 lung adenoid cystic carcinoma 10.3 HRAS KRAS
17 breast adenomyoepithelioma 10.3 ENO2 KRT7
18 breast myoepithelial neoplasm 10.3 ENO2 KRT7
19 gastric squamous cell carcinoma 10.3 ENO2 KRT7
20 respiratory system benign neoplasm 10.3 ENO2 KRAS
21 meningeal melanomatosis 10.3 ENO2 HRAS
22 nasal cavity cancer 10.3 CDX2 KRT7
23 chronic cystitis 10.3 CDX2 KRT7
24 vulva adenocarcinoma 10.3 CDX2 KRT7
25 rectum adenocarcinoma 10.3 CDX2 KRT7
26 somatostatinoma 10.3 ENO2 SST
27 thymus adenocarcinoma 10.3 CDX2 KRT7
28 gastric diffuse adenocarcinoma 10.3 CDX2 KRT7
29 sigmoid neoplasm 10.2 HRAS KRAS
30 mongolian spot 10.2 ENO2 SST
31 papillary transitional carcinoma 10.2 ENO2 KRT7
32 paronychia 10.2 HRAS KRAS
33 polyposis, skin pigmentation, alopecia, and fingernail changes 10.2 CDX2 MUC2
34 ovary neuroendocrine neoplasm 10.2 CDX2 KRT7
35 eyelid carcinoma 10.2 KRT7 MUC2
36 chronic cholangitis 10.2 CDX2 MUC2
37 retroperitoneal neuroblastoma 10.2 ENO2 SST
38 appendix adenocarcinoma 10.2 CDX2 KRT7
39 pancreatic cholera 10.2 MEN1 SST
40 mucinous adenofibroma 10.2 CDX2 KRT7
41 small cell carcinoma of the bladder 10.2 ENO2 KRT7
42 schimmelpenning-feuerstein-mims syndrome 10.2 HRAS KRAS
43 anus adenocarcinoma 10.2 CDX2 KRT7
44 glandular cystitis 10.2 CDX2 KRT7
45 sensory organ benign neoplasm 10.2 ENO2 KRT7
46 bladder urothelial carcinoma 10.2 HRAS KRAS KRT7
47 malignant ectomesenchymoma 10.2 ENO2 HRAS
48 ectomesenchymoma 10.2 ENO2 HRAS
49 paget disease, extramammary 10.2 KRT7 MUC1
50 duodenal somatostatinoma 10.2 ENO2 SST

Comorbidity relations with Duodenum Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Cholestasis
Deficiency Anemia Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Duodenum Cancer:



Diseases related to Duodenum Cancer

Symptoms & Phenotypes for Duodenum Cancer

UMLS symptoms related to Duodenum Cancer:


abdominal pain

GenomeRNAi Phenotypes related to Duodenum Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.47 HRAS KRAS MUC1
2 Decreased viability GR00106-A-0 9.47 KRAS
3 Decreased viability GR00221-A-1 9.47 HRAS KRAS
4 Decreased viability GR00221-A-2 9.47 HRAS KRAS
5 Decreased viability GR00221-A-3 9.47 HRAS
6 Decreased viability GR00301-A 9.47 KRAS
7 Decreased viability GR00381-A-1 9.47 KRAS
8 Decreased viability GR00402-S-2 9.47 HRAS KRAS MUC1

MGI Mouse Phenotypes related to Duodenum Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.63 CDX2 HRAS KRAS MEN1 MUC2 SST
2 homeostasis/metabolism MP:0005376 9.61 CDX2 HRAS KRAS KRT7 MEN1 MUC2
3 neoplasm MP:0002006 9.17 CDX2 HRAS KRAS MEN1 MUC2 MUTYH

Drugs & Therapeutics for Duodenum Cancer

Drugs for Duodenum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
2
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
3 Analgesics, Non-Narcotic Phase 2, Phase 3
4 Anti-Inflammatory Agents Phase 2, Phase 3
5 Antirheumatic Agents Phase 2, Phase 3
6 Cyclooxygenase 2 Inhibitors Phase 2, Phase 3
7 Peripheral Nervous System Agents Phase 2, Phase 3
8 Gastrointestinal Agents Phase 2, Phase 3,Not Applicable
9 Analgesics Phase 2, Phase 3
10 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
11 Cholagogues and Choleretics Phase 2, Phase 3
12 Cyclooxygenase Inhibitors Phase 2, Phase 3
13
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
14
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
15
leucovorin Approved Phase 2 58-05-9 6006 143
16
Pancrelipase Approved, Investigational Phase 2,Phase 1,Not Applicable 53608-75-6
17
Fluorouracil Approved Phase 2 51-21-8 3385
18
Nivolumab Approved Phase 2 946414-94-4
19
Rivaroxaban Approved Phase 2 366789-02-8
20
Heparin Approved, Investigational Phase 2 9005-49-6 772 46507594
21
Dalteparin Approved Phase 2 9005-49-6
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
23
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
24 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
25 Vitamins Phase 2
26 Calcium, Dietary Phase 2
27 Vitamin B9 Phase 2
28 Trace Elements Phase 2
29 Immunologic Factors Phase 2,Phase 1
30 Antidotes Phase 2
31 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
32 Antimetabolites, Antineoplastic Phase 2,Phase 1
33 Folate Phase 2
34 pancreatin Phase 2,Phase 1,Not Applicable
35 Antimetabolites Phase 2,Phase 1
36 Protective Agents Phase 2
37 topoisomerase I inhibitors Phase 2,Phase 1
38 Bone Density Conservation Agents Phase 2
39 Vitamin B Complex Phase 2
40 Topoisomerase Inhibitors Phase 2,Phase 1
41 Micronutrients Phase 2
42 Immunosuppressive Agents Phase 2,Phase 1
43 Antibodies Phase 2
44 Antibodies, Monoclonal Phase 2
45 Immunoglobulins Phase 2
46 Serine Proteinase Inhibitors Phase 2
47 calcium heparin Phase 2
48 HIV Protease Inhibitors Phase 2
49 Factor Xa Inhibitors Phase 2
50
protease inhibitors Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
2 Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
3 Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Completed NCT01731821 Phase 3
4 Study of Gastroduodenal Metallic Stent vs Gastrojejunostomy Recruiting NCT02784470 Phase 3
5 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
6 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
7 A Randomized Phase II Study to Compare the Safety and Efficacy of Dalteparin vs. Rivaroxaban for Cancer-associated Venous Thromboembolism Recruiting NCT03139487 Phase 2 Rivaroxaban;Dalteparin
8 Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer Withdrawn NCT00487851 Phase 2
9 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
10 Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers Completed NCT00183846 Phase 1 irinotecan
11 Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science Recruiting NCT03189992 Phase 1 Bushen-Jianpi Dedoction;cinobufotalin injection
12 A Study of Guselkumab in Participants With Familial Adenomatous Polyposis Recruiting NCT03649971 Phase 1 Guselkumab;Placebo
13 Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy Unknown status NCT02954302 Not Applicable
14 Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) Unknown status NCT02656134
15 Comparing the Efficacy of Endoscopic FNA vs FNB in Diagnosing Solid Gastrointestinal Lesions Unknown status NCT01698190 Not Applicable
16 Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy Unknown status NCT00915863 Not Applicable
17 Duodenal Cancer - Retrospective Analysis Completed NCT01661049
18 A Pan-European Study on Minimally Invasive Versus Open Pancreatoduodenectomy in High-volume Centers Completed NCT03172572
19 Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy Completed NCT00639314 Not Applicable
20 Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy Completed NCT00628186 Not Applicable
21 Postoperative Oral Nutritional Supplementation After Major Gastrointestinal Surgery Completed NCT01838109 Not Applicable
22 The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery Completed NCT02381249 Not Applicable Octreotide;Placebo
23 Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies Completed NCT03525067
24 Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE) Completed NCT02312167 Not Applicable
25 Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality Completed NCT02378337
26 Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP) Recruiting NCT03346980
27 Enteral Nutrition After Pancreaticoduodenectomy Recruiting NCT03150615 Not Applicable
28 Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions Recruiting NCT01750619
29 Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders Recruiting NCT01438385
30 Endoscopic Resection Multicenter Registry Recruiting NCT03065257
31 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
32 Pancreaticoduodenectomy With or Without Preoperative Hyperbaric Oxygen Therapy Enrolling by invitation NCT02575014 Not Applicable Preoperative hyperbaric oxygen
33 Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy Not yet recruiting NCT03631173 Not Applicable
34 Magnetic Compressive Anastomosis for Biliojejunostomy and Pancreaticojejunostomy During Whipple's Procedure Not yet recruiting NCT03792048 Not Applicable
35 A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy Terminated NCT00359320 Not Applicable
36 Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer Terminated NCT00899132
37 Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery Withdrawn NCT02446379 The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose

Search NIH Clinical Center for Duodenum Cancer

Cochrane evidence based reviews: duodenal neoplasms

Genetic Tests for Duodenum Cancer

Anatomical Context for Duodenum Cancer

MalaCards organs/tissues related to Duodenum Cancer:

41
Small Intestine, Lung, Liver, Breast, Ovary, Pancreas, Appendix

The Foundational Model of Anatomy Ontology organs/tissues related to Duodenum Cancer:

19
The Beginning Section Of The Small Intestine

Publications for Duodenum Cancer

Articles related to Duodenum Cancer:

# Title Authors Year
1
Duodenum Cryptococcosis Mimicking Primary Duodenum Cancer on PET/CT Imaging. ( 29538024 )
2018
2
Upper GI tract lesions in familial adenomatous polyposis (FAP): enrichment of pyloric gland adenomas and other gastric and duodenal neoplasms. ( 24525509 )
2014

Variations for Duodenum Cancer

Expression for Duodenum Cancer

Search GEO for disease gene expression data for Duodenum Cancer.

Pathways for Duodenum Cancer

GO Terms for Duodenum Cancer

Cellular components related to Duodenum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC6

Biological processes related to Duodenum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of long-term neuronal synaptic plasticity GO:0048169 9.32 HRAS KRAS
2 maintenance of gastrointestinal epithelium GO:0030277 9.26 MUC2 MUC6
3 response to isolation stress GO:0035900 9.16 HRAS KRAS
4 O-glycan processing GO:0016266 9.13 MUC1 MUC2 MUC6
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 HRAS KRAS MUC1 MUC2 MUC6

Molecular functions related to Duodenum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded DNA binding GO:0003690 9.33 CDX2 MEN1 NTHL1
2 DNA N-glycosylase activity GO:0019104 8.96 MUTYH NTHL1
3 hydrolase activity, acting on glycosyl bonds GO:0016798 8.8 MANEAL MUTYH NTHL1

Sources for Duodenum Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....